Upgrade to SI Premium - Free Trial

Arbutus Biopharma (ABUS)

4.21 -0.04 (0.94%)

Chart
Today 6M 1Y 5Y

Upcoming Events

- Earnings (7/30/26)

Latest Headlines

Form S-8 Arbutus Biopharma Corp June 5, 2026 4:06 PM - SEC Filing Form 8-K Arbutus Biopharma Corp For: May 26 May 27, 2026 4:02 PM - SEC Filing Form SCHEDULE 13G/A Arbutus Biopharma Corp Filed by: Two Seas Capital LP May 15, 2026 5:34 PM - SEC Filing Arbutus Biopharma (ABUS) Tops Q1 EPS by 91c May 13, 2026 7:47 AM - StreetInsider Form 10-Q Arbutus Biopharma Corp For: Mar 31 May 13, 2026 7:32 AM - SEC Filing Form 8-K Arbutus Biopharma Corp For: May 13 May 13, 2026 7:31 AM - SEC Filing Arbutus Reports First Quarter 2026 Financial Results and Provides Corporate Update May 13, 2026 7:30 AM - Globe NewsWire Form SCHEDULE 13D/A Arbutus Biopharma Corp Filed by: Whitefort Capital Management, LP April 28, 2026 5:55 PM - SEC Filing Form 8-K Arbutus Biopharma Corp For: Apr 14 April 15, 2026 7:32 AM - SEC Filing Arbutus receives FDA fast track status for hepatitis B drug imdusiran April 15, 2026 7:30 AM - StreetInsider Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B April 15, 2026 7:30 AM - StreetInsider Form DEFA14A Arbutus Biopharma Corp April 14, 2026 5:05 PM - SEC Filing Form DEF 14A Arbutus Biopharma Corp For: May 26 April 14, 2026 5:02 PM - SEC Filing Form SCHEDULE 13D/A Arbutus Biopharma Corp Filed by: Whitefort Capital Management, LP April 13, 2026 7:56 PM - SEC Filing Arbutus Biopharma (ABUS) Misses Q4 EPS by 14c March 23, 2026 9:11 PM - StreetInsider Form 8-K Arbutus Biopharma Corp For: Mar 23 March 23, 2026 7:31 AM - SEC Filing Form 10-K Arbutus Biopharma Corp For: Dec 31 March 23, 2026 7:31 AM - SEC Filing Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update March 23, 2026 7:30 AM - StreetInsider Full Article List